Elastagen Pty Ltd, a clinical stage company developing medical device products based on recombinant tropoelastin, today announced that it has entered into a definitive agreement under which Allergan plc, a leading global biopharmaceutical company, has agreed to acquire Elastagen.

The deal will consist of an upfront payment of US$95 million (AUD$120 million) plus contingent, commercial payments.

Elastagen’s revolutionary technology is based on recombinant human tropoelastin, the self-assembling elastic protein which allows the body to repair elastic tissues in the skin, artery, bladder and lung… Continue reading.